“Use of the 40-Gene Expression Profile (40-GEP) Test in Medicare-Eligible Patients Diagnosed With Cutaneous Squamous Cell Carcinoma (cSCC) to Guide Adjuvant Radiation Therapy (ART) Decisions Leads to a Significant Reduction in Healthcare Costs ”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 1, Jan. 2024, p. s336, https://doi.org/10.25251/skin.8.supp.336.